TY - JOUR
T1 - Multiple myeloma in patients up to 30 years of age
T2 - a multicenter retrospective study of 52 cases
AU - Jurczyszyn, Artur
AU - Davila, Julio
AU - Kortüm, K. Martin
AU - Jayabalan, David S.
AU - Vij, Ravi
AU - Fiala, Mark
AU - Milunovic, Vibor
AU - Chim, C. S.
AU - Wiśniewska-Piąty, Katarzyna
AU - Waszczuk-Gajda, Anna
AU - Crusoe, Edvan
AU - Hajek, Roman
AU - Robak, Paweł
AU - Raźny, Małgorzata
AU - Zawirska, Daria
AU - Bittrich, Max
AU - Nahi, Hareth
AU - Liu, Jieqi
AU - Castillo, Jorge J.
AU - Vesole, David H.
N1 - Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/1/28
Y1 - 2019/1/28
N2 - A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.
AB - A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.
KW - Early-onset multiple myeloma
KW - prognosis
KW - survival
KW - treatment response
UR - http://www.scopus.com/inward/record.url?scp=85050555358&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1480766
DO - 10.1080/10428194.2018.1480766
M3 - Article
C2 - 30033832
AN - SCOPUS:85050555358
SN - 1042-8194
VL - 60
SP - 471
EP - 476
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -